Using Alpha 4 Beta 2 Selective Positive Allosteric Modulators for the Treatment of OCD and OCD Spectrum Disorders


The Market: Pharmaceutical companies



This invention addresses the problem of developing a drug therapy for the treatment of obsessive

compulsive (OCD) spectrum disorders. Current approaches to the treatment of OCD typically

involve the use of antidepressants classically categorized as selective serotonin reuptake

inhibitors. These medications are broad acting, often not specifically approved for OCD and

often require several weeks to show efficacy.


Competitive Advantage:

This invention is novel in that it utilizes a new

approach to the treatment of OCD by targeting a novel receptor. This invention produces more

rapid and immediate effect and by selectively targeting a specific subtype of receptor, will likely

show fewer side effects.


Patent Information:
For Information, Contact:
Melissa Mccumby
University of Alaska Fairbanks
Abel Bult-Ito
Swarup Mitra
© 2021. All Rights Reserved. Powered by Inteum